Financial giants have made a conspicuous bullish move on Johnson & Johnson. Our analysis of options history for Johnson & Johnson JNJ revealed 12 unusual trades.
Delving into the details, we found 75% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we spotted, 8 were puts, with a value of $448,993, and 4 were calls, valued at $249,736.
What's The Price Target?
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $120.0 to $165.0 for Johnson & Johnson over the last 3 months.
Volume & Open Interest Trends
In today's trading context, the average open interest for options of Johnson & Johnson stands at 1807.17, with a total volume reaching 2,748.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Johnson & Johnson, situated within the strike price corridor from $120.0 to $165.0, throughout the last 30 days.
Johnson & Johnson 30-Day Option Volume & Interest Snapshot
Noteworthy Options Activity:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| JNJ | CALL | SWEEP | BEARISH | 05/17/24 | $165.00 | $135.1K | 3.9K | 556 |
| JNJ | PUT | SWEEP | BULLISH | 01/16/26 | $150.00 | $119.0K | 1.1K | 276 |
| JNJ | PUT | SWEEP | BULLISH | 01/16/26 | $150.00 | $103.1K | 1.1K | 353 |
| JNJ | PUT | SWEEP | BULLISH | 01/16/26 | $150.00 | $50.4K | 1.1K | 57 |
| JNJ | PUT | SWEEP | BULLISH | 06/20/25 | $150.00 | $46.9K | 1.4K | 141 |
About Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.
Following our analysis of the options activities associated with Johnson & Johnson, we pivot to a closer look at the company's own performance.
Where Is Johnson & Johnson Standing Right Now?
- With a volume of 3,552,032, the price of JNJ is up 0.4% at $160.48.
- RSI indicators hint that the underlying stock may be approaching overbought.
- Next earnings are expected to be released in 42 days.
What The Experts Say On Johnson & Johnson
A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $203.66666666666666.
- In a cautious move, an analyst from RBC Capital downgraded its rating to Outperform, setting a price target of $181.
- An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $215.
- An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $215.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Johnson & Johnson, Benzinga Pro gives you real-time options trades alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
